Results 81 to 90 of about 42,500 (221)

Current strategies against invasive fungal infections in patients with aplastic anemia, strong power and weak weapon, a case report and review of literature

open access: yesMedical Mycology Case Reports, 2016
We report an 18 year old boy with Aplastic anemia complicated by serious fungal rhinosinusitis. Despite prompt treatment and early repeated surgical debridements, he died after about more than 6 weeks of hard challenges with fungal infections.
Omid Reza Zekavat   +6 more
doaj   +1 more source

Challenges of Dengue in Hematological Disease Patients: Descriptive Analysis From the DANGO Registry During the 2023–2024 Outbreak in Argentina

open access: yesTransplant Infectious Disease, EarlyView.
During the 2023–2024 Argentine dengue outbreak, 33 patients with hematological disease showed high complication rates, frequent hospitalization (64%), severe thrombocytopenia (90%), and 6% dengue‐attributable mortality. Transfusion‐associated cases were documented.
Gustavo Adolfo Méndez   +16 more
wiley   +1 more source

Early evidence of bone marrow dysfunction in children with indeterminate fulminant hepatic failure who ultimately develop aplastic anemia. [PDF]

open access: yes, 2004
In children, aplastic anemia (AA) is a common complication associated with fulminant hepatic failure (FHF). The objective of this study was to determine whether specific pretransplantation clinical and laboratory characteristics can be used to ...
Ingram-Drake, Leslie   +6 more
core  

Adding eltrombopag to immunosuppression: the importance of predicting outcome

open access: yesHaematologica, 2021
André Tichelli   +3 more
doaj   +1 more source

Deep sequencing and flow cytometric characterization of expanded effector memory CD8+CD57+ T cells frequently reveals T-cell receptor Vβ oligoclonality and CDR3 homology in acquired aplastic anemia

open access: yesHaematologica, 2018
Oligoclonal expansion of CD8+ CD28− lymphocytes has been considered indirect evidence for a pathogenic immune response in acquired aplastic anemia. A subset of CD8+ CD28− cells with CD57 expression, termed effector memory cells, is expanded in several ...
Valentina Giudice   +8 more
doaj   +1 more source

Clinical application of a modified platelet desialylation test for mechanistic characterization of platelet transfusion refractoriness

open access: yesTransfusion, EarlyView.
Abstract Background Platelet transfusion refractoriness (PTR) is a major challenge in transfusion medicine and may result from both immune and non‐immune mechanisms. Although alloantibodies are well‐established contributors, Fc‐independent pathways such as platelet desialylation have emerged as alternative mechanisms of clearance.
Karen Ziza   +11 more
wiley   +1 more source

Diagnosis, Diagnosis Differensial dan Penatalaksanaan Immunosupresif dan Terapi Sumsum Tulang pada Pasien Anemia Aplastik

open access: yese-Jurnal Medika Udayana, 2014
Anemia aplastic is anemia with bone marrow failure characterized by pancytopenia and at themost case with hypoplasia bone marrow. The incidence of anemia aplastic is 3 -6 case per 1million persons per year.
Thaha ..   +2 more
doaj  

Acute lymphoblastic leukemia of childhood presenting as aplastic anemia: report of two cases

open access: yesRevista Brasileira de Hematologia e Hemoterapia, 2012
Acute lymphoblastic leukemia is the most common malignancy in pediatric patients; its diagnosis is usually easy to establish as malignant lymphoblasts invade the bone marrow and peripheral blood.
Laura Villarreal-Martínez   +4 more
doaj   +1 more source

Child with aplastic anemia: Anesthetic management

open access: yesSaudi Journal of Anaesthesia, 2012
Aplastic anemia is a rare heterogeneous disorder of hematopoietic stem cells causing pancytopenia and marrow hypoplasia with the depletion of all types of blood cells.
Manpreet Kaur   +3 more
doaj   +1 more source

Real‐World Effectiveness and Safety of Ravulizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria: Evidence From the International PNH Registry

open access: yesAmerican Journal of Hematology, Volume 101, Issue 5, Page 939-948, May 2026.
ABSTRACT Ravulizumab, a second‐generation complement component 5 inhibitor (C5i) derived from eculizumab, with improved pharmacokinetics, is the current standard‐of‐care treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), where available.
Alexander Röth   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy